PortalPublikationenPrognostic utility of the cell cycle progression score gener...

Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy

Standard

Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. / Bishoff, Jay T; Freedland, Stephen J; Gerber, Leah; Tennstedt, Pierre; Reid, Julia; Welbourn, William; Graefen, Markus; Sangale, Zaina; Tikishvili, Eliso; Park, Jimmy; Younus, Adib; Gutin, Alexander; Lanchbury, Jerry S; Sauter, Guido; Brawer, Michael; Stone, Steven; Schlomm, Thorsten.

in: J UROLOGY, Jahrgang 192, Nr. 2, 01.08.2014, S. 409-14.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Bishoff, JT, Freedland, SJ, Gerber, L, Tennstedt, P, Reid, J, Welbourn, W, Graefen, M, Sangale, Z, Tikishvili, E, Park, J, Younus, A, Gutin, A, Lanchbury, JS, Sauter, G, Brawer, M, Stone, S & Schlomm, T 2014, 'Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy', J UROLOGY, Jg. 192, Nr. 2, S. 409-14. https://doi.org/10.1016/j.juro.2014.02.003

APA

Bishoff, J. T., Freedland, S. J., Gerber, L., Tennstedt, P., Reid, J., Welbourn, W., Graefen, M., Sangale, Z., Tikishvili, E., Park, J., Younus, A., Gutin, A., Lanchbury, J. S., Sauter, G., Brawer, M., Stone, S., & Schlomm, T. (2014). Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J UROLOGY, 192(2), 409-14. https://doi.org/10.1016/j.juro.2014.02.003

Vancouver

Bishoff JT, Freedland SJ, Gerber L, Tennstedt P, Reid J, Welbourn W et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J UROLOGY. 2014 Aug 1;192(2):409-14. https://doi.org/10.1016/j.juro.2014.02.003

Bibtex

@article{5e02af31b98143fbaf284276fc6f95be,
title = "Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy",
abstract = "PURPOSE: The cell cycle progression score is associated with prostate cancer outcomes in various clinical settings. However, previous studies of men treated with radical prostatectomy evaluated cell cycle progression scores generated from resected tumor tissue. We evaluated the prognostic usefulness of the score derived from biopsy specimens in men treated with radical prostatectomy.MATERIALS AND METHODS: We evaluated the cell cycle progression score in cohorts of patients from the Martini Clinic (283), Durham Veterans Affairs Medical Center (176) and Intermountain Healthcare (123). The score was derived from simulated biopsy (Martini Clinic) or diagnostic biopsy (Durham Veterans Affairs Medical Center and Intermountain Healthcare) and evaluated for an association with biochemical recurrence and metastatic disease.RESULTS: In all 3 cohorts the cell cycle progression score was associated with biochemical recurrence and metastatic disease. The association with biochemical recurrence remained significant after adjusting for other prognostic clinical variables. On combined analysis of all cohorts (total 582 patients) the score was a strong predictor of biochemical recurrence on univariate analysis (HR per score unit 1.60, 95% CI 1.35-1.90, p = 2.4 × 10(-7)) and multivariate analysis (HR per score unit 1.47, 95% CI 1.23-1.76, p = 4.7 × 10(-5)). Although there were few events (12), the cell cycle progression score was the strongest predictor of metastatic disease on univariate analysis (HR per score unit 5.35, 95% CI 2.89-9.92, p = 2.1 × 10(-8)) and after adjusting for clinical variables (HR per score unit 4.19, 95% CI 2.08-8.45, p = 8.2 × 10(-6)).CONCLUSIONS: The cell cycle progression score derived from a biopsy sample was associated with adverse outcomes after surgery. These results indicate that the score can be used at disease diagnosis to better define patient prognosis and enable more appropriate clinical care.",
author = "Bishoff, {Jay T} and Freedland, {Stephen J} and Leah Gerber and Pierre Tennstedt and Julia Reid and William Welbourn and Markus Graefen and Zaina Sangale and Eliso Tikishvili and Jimmy Park and Adib Younus and Alexander Gutin and Lanchbury, {Jerry S} and Guido Sauter and Michael Brawer and Steven Stone and Thorsten Schlomm",
note = "Copyright {\textcopyright} 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.",
year = "2014",
month = aug,
day = "1",
doi = "10.1016/j.juro.2014.02.003",
language = "English",
volume = "192",
pages = "409--14",
journal = "J UROLOGY",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy

AU - Bishoff, Jay T

AU - Freedland, Stephen J

AU - Gerber, Leah

AU - Tennstedt, Pierre

AU - Reid, Julia

AU - Welbourn, William

AU - Graefen, Markus

AU - Sangale, Zaina

AU - Tikishvili, Eliso

AU - Park, Jimmy

AU - Younus, Adib

AU - Gutin, Alexander

AU - Lanchbury, Jerry S

AU - Sauter, Guido

AU - Brawer, Michael

AU - Stone, Steven

AU - Schlomm, Thorsten

N1 - Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - PURPOSE: The cell cycle progression score is associated with prostate cancer outcomes in various clinical settings. However, previous studies of men treated with radical prostatectomy evaluated cell cycle progression scores generated from resected tumor tissue. We evaluated the prognostic usefulness of the score derived from biopsy specimens in men treated with radical prostatectomy.MATERIALS AND METHODS: We evaluated the cell cycle progression score in cohorts of patients from the Martini Clinic (283), Durham Veterans Affairs Medical Center (176) and Intermountain Healthcare (123). The score was derived from simulated biopsy (Martini Clinic) or diagnostic biopsy (Durham Veterans Affairs Medical Center and Intermountain Healthcare) and evaluated for an association with biochemical recurrence and metastatic disease.RESULTS: In all 3 cohorts the cell cycle progression score was associated with biochemical recurrence and metastatic disease. The association with biochemical recurrence remained significant after adjusting for other prognostic clinical variables. On combined analysis of all cohorts (total 582 patients) the score was a strong predictor of biochemical recurrence on univariate analysis (HR per score unit 1.60, 95% CI 1.35-1.90, p = 2.4 × 10(-7)) and multivariate analysis (HR per score unit 1.47, 95% CI 1.23-1.76, p = 4.7 × 10(-5)). Although there were few events (12), the cell cycle progression score was the strongest predictor of metastatic disease on univariate analysis (HR per score unit 5.35, 95% CI 2.89-9.92, p = 2.1 × 10(-8)) and after adjusting for clinical variables (HR per score unit 4.19, 95% CI 2.08-8.45, p = 8.2 × 10(-6)).CONCLUSIONS: The cell cycle progression score derived from a biopsy sample was associated with adverse outcomes after surgery. These results indicate that the score can be used at disease diagnosis to better define patient prognosis and enable more appropriate clinical care.

AB - PURPOSE: The cell cycle progression score is associated with prostate cancer outcomes in various clinical settings. However, previous studies of men treated with radical prostatectomy evaluated cell cycle progression scores generated from resected tumor tissue. We evaluated the prognostic usefulness of the score derived from biopsy specimens in men treated with radical prostatectomy.MATERIALS AND METHODS: We evaluated the cell cycle progression score in cohorts of patients from the Martini Clinic (283), Durham Veterans Affairs Medical Center (176) and Intermountain Healthcare (123). The score was derived from simulated biopsy (Martini Clinic) or diagnostic biopsy (Durham Veterans Affairs Medical Center and Intermountain Healthcare) and evaluated for an association with biochemical recurrence and metastatic disease.RESULTS: In all 3 cohorts the cell cycle progression score was associated with biochemical recurrence and metastatic disease. The association with biochemical recurrence remained significant after adjusting for other prognostic clinical variables. On combined analysis of all cohorts (total 582 patients) the score was a strong predictor of biochemical recurrence on univariate analysis (HR per score unit 1.60, 95% CI 1.35-1.90, p = 2.4 × 10(-7)) and multivariate analysis (HR per score unit 1.47, 95% CI 1.23-1.76, p = 4.7 × 10(-5)). Although there were few events (12), the cell cycle progression score was the strongest predictor of metastatic disease on univariate analysis (HR per score unit 5.35, 95% CI 2.89-9.92, p = 2.1 × 10(-8)) and after adjusting for clinical variables (HR per score unit 4.19, 95% CI 2.08-8.45, p = 8.2 × 10(-6)).CONCLUSIONS: The cell cycle progression score derived from a biopsy sample was associated with adverse outcomes after surgery. These results indicate that the score can be used at disease diagnosis to better define patient prognosis and enable more appropriate clinical care.

U2 - 10.1016/j.juro.2014.02.003

DO - 10.1016/j.juro.2014.02.003

M3 - SCORING: Journal article

C2 - 24508632

VL - 192

SP - 409

EP - 414

JO - J UROLOGY

JF - J UROLOGY

SN - 0022-5347

IS - 2

ER -